[ad_1]

The National Stock Exchange of India (NSE) will introduce futures and options (F&O) contracts on three additional securities—Fortis Healthcare, Piramal Pharma and UNO Minda—from May 30, 2025, the exchange said in a circular on May 7.

The contracts will be launched following approval from the Securities and Exchange Board of India (SEBI) and based on the stock selection criteria outlined in SEBI’s August 2024 circular. NSE noted that the contracts are subject to fulfilment of the eligibility requirements under the Quarter sigma computation cycle for May 2025.

The exchange will issue a separate circular on May 29 to communicate the market lot and strike price scheme for the new contracts. Members have been advised to upload the updated contract files in their trading applications before trading begins on May 30. Information on applicable quantity freeze limits will also be included in the contract file for the day.

The move follows NSE’s recent decision to defer the implementation of a new expiry schedule for F&O contracts. On March 28, the exchange postponed its plan to shift expiry days for key indices—including Nifty, Bank Nifty, FinNifty, Nifty Next50 and Nifty Midcap Select—to Mondays. The change, originally slated to take effect from April 4, was held back after SEBI released a consultation paper proposing that all equity derivatives expiries be restricted to either Tuesdays or Thursdays.

The proposal is intended to ensure better spacing of expiries across exchanges while avoiding the use of Mondays or Fridays.


Also read | NSE defers move to change F&O expiry day to Monday until further notice(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

[ad_2]

Source link

By Ajay ji

One thought on “NSE to launch F&O contracts on Piramal Pharma and 2 other securities from May 30”
  1. The bank’s performance this quarter seems quite impressive, especially with the 22% rise in PAT and the consistent growth in NII. It’s interesting to see how the interest income has increased both YoY and QoQ, reflecting a strong financial position. The improvement in Gross and Net NPA ratios is also a positive sign, indicating better asset quality. However, the rise in interest expenses by 12% YoY is something to keep an eye on—could this impact future profitability? The dividend recommendation of Rs 4 per share is a good move, but how sustainable is this in the long term given the current economic climate? Overall, the numbers look solid, but I’m curious about the strategies in place to maintain this growth trajectory. What are your thoughts on the bank’s approach to managing its credit costs and deposits?

Leave a Reply

Your email address will not be published. Required fields are marked *